Novel Application of a CD25-Targeted, Pyrrolobenzodiazepine (PBD) Dimer-Based ADC as Immunotherapeutic Agent

Time: 9:00 am
day: Day One


  • Currently, ADCs are predominantly used to directly target antigen-positive tumour cells
  • This presentation will provide proof-of-concept for a novel application of a CD25-targeted, PBD-based ADC as immunotherapeutic agent, since the main mode of action relies on the ADC directly targeting T regulatory immune cells, rather than tumour cells
  • Additional data will be presented showing promising combination partners tested with the CD25-ADC in preclinical models